The most comprehensive and one of the fastest scientific meeting report services aimed at the pharmaceutical industry is now available to subscribers to Current Drugs’ latest database, IDdb3. From tomorrow (24 March) IDdb editors will be reporting overnight from the American Association for Cancer Research 92nd Annual Meeting in New Orleans, LA, USA.
“The AACR meeting is one of the world’s most important cancer conferences. We will be reporting on pre-clinical and clinical information, new therapies, advances, and more. Plus, we will be evaluating around 6,000 abstracts for their relevance to drug discovery and development,” said Tara Dyson, Director of the database’s editorial team. “More drugs are reported for the first time at scientific meetings than anywhere else. So for anyone needing the most up-to-date information on therapies in development our service is vital.”
Using a network of 2,000 scientists plus their own editors Current Drugs publishes 700 reports a year from 400 meetings around the world. Current Drugs’ in-house staff cover about 25 major conferences and their daily reports are posted overnight on IDdb3. The rest of the meeting coverage is based on reports from delegates who are research scientists in academia or industry.
“The advantage of using our own editors and active scientists in the field is that they not only report the facts, but put them into context,” commented Tara Dyson. “Plus, they interview speakers and collect information from poster sessions to gain unique information such as the current development status of a drug.”
The IDdb3 meeting report service is one of the fastest available. Apart from the overnight reports from major conferences the rest of the reports are published within two weeks of the end of the conference.
Added Charlotte Worker, IDdb’s Meetings Managing Editor: “Our service is faster and has broader coverage than more traditional suppliers. Most of them publish within three to four weeks of a meeting and none has such an extensive range.”
Before major meetings, Current Drugs publishes previews highlighting the hot topics to be covered. In addition, summary reports listing all new drugs, updated drugs and links to all reports from the meetings are published after completion of coverage. Thus giving easy access to all the important information disclosed.
The topics incorporated in the reports cover a wide range of subjects including: disclosure of investigational drugs, clinical trials, pharmaceutical and business strategy, and enabling technologies.
Information from the meeting reports is used to update other sections in IDdb3, particularly the individual records on investigational drugs. Hyperlinks to other areas of the database including patent, drug and company records are also provided. In addition, the database contains an archive of almost 2,500 reports of conferences covered since 1996.
Further information on IDdb3, including self-running demos, can be found on its Web site http://www.iddb3.com
Notes to Editors:
1) IDdb3 is a pharmaceutical intelligence service that tracks developmental drugs from the first patent publication through to eventual launch or discontinuation.
2) The American Association for Cancer Research 92nd Annual Meeting in New Orleans, LA, USA runs from 24 to 28 March. http://www.aacr.org
Current Drugs Ltd - the world's leading supplier of intelligence services for pharmaceutical R&D. Current Drugs Ltd is headquartered in London, UK and has offices in Philadelphia, USA and Tokyo, Japan. It provides databases, journals and customized software services to the international pharmaceutical industry and is part of the privately owned Current Science Group of companies. http://www.current-drugs.com
MEDIA CONTACT (details not for publication please):
Christine Suggars, Media & Communications Manager. Tel: +44-(0)20-7631-9147 (direct line), Fax: +44-(0)20-7580-5646. Tel/Fax: +44-(0)1480-217110 (home). E-mail: email@example.com
This press release was distributed by ResponseSource Press Release Wire on behalf of Current Drugs in the following categories: Consumer Technology, Personal Finance, Business & Finance, Computing & Telecoms, for more information visit https://pressreleasewire.responsesource.com/about.